within Pharmacolibrary.Drugs.S_SensoryOrgans.S01H_LocalAnesthetics.S01HA01_Cocaine;

model Cocaine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 0.00012226666666666667,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.0027,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0018,
    k12 = 9.666666666666665e-05,
    k21 = 9.666666666666665e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cocaine</td></tr><tr><td>ATC code:</td><td>S01HA01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>104.8</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cocaine is a tropane alkaloid with local anesthetic and central nervous system stimulant properties. It blocks the reuptake of neurotransmitters such as dopamine, norepinephrine, and serotonin. In medicine, it has been used for topical anesthesia of mucous membranes, particularly in ophthalmological and otorhinolaryngological procedures. Its medical use is now highly restricted due to significant potential for abuse and toxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data from healthy adult males following intravenous administration during clinical local anesthetic procedures.</p><h4>References</h4><ol><li><p>Rook, EJ, et al., &amp; Beijnen, JH (2006). Population pharmacokinetics of heroin and its major metabolites. <i>Clinical pharmacokinetics</i> 45(4) 401–417. DOI:<a href=\"https://doi.org/10.2165/00003088-200645040-00005\">10.2165/00003088-200645040-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16584286/\">https://pubmed.ncbi.nlm.nih.gov/16584286</a></p></li><li><p>van Amsterdam, J, &amp; van den Brink, W (2025). Explaining the high mortality among opioid-cocaine co-users compared to opioid-only users. A systematic review. <i>Journal of addictive diseases</i> 43(2) 121–131. DOI:<a href=\"https://doi.org/10.1080/10550887.2024.2331522\">10.1080/10550887.2024.2331522</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38504419/\">https://pubmed.ncbi.nlm.nih.gov/38504419</a></p></li><li><p>Fattinger, K, et al., &amp; Verotta, D (2000). Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine. <i>European journal of clinical pharmacology</i> 56(4) 305–310. DOI:<a href=\"https://doi.org/10.1007/s002280000147\">10.1007/s002280000147</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10954344/\">https://pubmed.ncbi.nlm.nih.gov/10954344</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01HA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cocaine;
